Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2–ACE2 Receptor Interactions
Christopher J. Day,
Benjamin Bailly,
Patrice Guillon,
Larissa Dirr,
Freda E.-C. Jen,
Belinda L. Spillings,
Johnson Mak,
Mark von Itzstein,
Thomas Haselhorst,
Michael P. Jennings
Affiliations
Christopher J. Day
Institute for Glycomics, Griffith University, Gold Coast Campus, Gold Coast, QLD, Australia
SARS-CoV-2, the causative agent of COVID-19, has caused more than 60 million cases worldwide with almost 1.5 million deaths as of November 2020. Repurposing existing drugs is the most rapid path to clinical intervention for emerging diseases.
